Valeritas today postponed its planned initial public offering, which at the midpoint was slated to fetch $75 million for its V-Go basal insulin delivery system for Type II diabetes, Renaissance Capital reported.
Earlier this month Valeritas said it planned to put up 5 million shares at $14 to $16 each.